Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 20, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade

These findings reinforce the importance of continuing to deepen our understanding of the underlying biology that drives both growth and resistance.
May 20, 2026 07:00 ET | Source: Grey Matters Health Inc.

Grey Matters Health Signs LOI with Catalyst MedTech for 200 Brain PET Scans for Alzheimer’s Clinical Trial at 2nd NovaScan Location Planned for Tampa

VANCOUVER, British Columbia, May 20, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “Company” or “Grey Matters”) (CSE: GREY) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company,...
May 20, 2026 07:00 ET | Source: 4basebio

4basebio Signs Clinical Supply Agreement to Support Phase II Clinical Trial

Oncology focused biotech to utilise 4basebio’s opDNA® technology to support Phase II clinical trial of immunotherapy candidate Multi-year, seven-figure revenue stream reflecting increased commercial...
May 19, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients

After a thorough process, management are pleased to undertake this pivotal step for GMP production of PRP for the upcoming Phase 1 FIH clinical study
May 19, 2026 08:00 ET | Source: Matisse Pharmaceuticals

Matisse Pharmaceuticals receives FDA IND clearance for isupartob sodium

Matisse Pharmaceuticals announces U.S. FDA clearance of the company’s Investigational New Drug (IND) application for isupartob sodium
May 19, 2026 03:30 ET | Source: Mestag Therapeutics

Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial

Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial
May 19, 2026 02:00 ET | Source: Khondrion B.V.

Khondrion Announces First Patient Dosed in Phase II Study Targeting Debilitating Post-COVID Fatigue

Khondrion announced that the first patient has been dosed in the Phase II SON4PEM study evaluating sonlicromanol in Post-COVID.
May 18, 2026 08:30 ET | Source: Medidata Solutions, Inc.

Medidata’s Second Annual AI Report Shows a Shift from Pilots to Enterprise Adoption with 72.9% of Early Adopters Seeing a Reduction in Study Timelines

NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today released its second annual report...
May 15, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results

An update on corporate progress and reported third quarter financial results as of March 31, 2026 (Year end June 30).
May 11, 2026 08:00 ET | Source: Jabez Biosciences, Inc.

Jabez Biosciences Presents First-in-Human Pharmacokinetic and Pharmacodynamic Data for JBZ-001 at AACR Annual Meeting 2026

Phase 1 Clinical Data Demonstrate Dose-Proportional PK, No Dose-Limiting Toxicities Through Four Dose Levels, and Concordance with Preclinical PBPK Predictions CRANBERRY TOWNSHIP, Pa., May 11, 2026 ...